Smaller and shorter early-phase trials were more likely to complete, whereas novel trial designs were not associated with faster completion. Direct-acting antivirals showed marked end-of-treatment HBsAg decline, an on-treatment signal rather than durable functional cure.
Shi et al. (Fri,) studied this question.